Rakovina Therapeutics

News & Media

Press Releases

May 30, 2023: Management discussion and analysis

May 30, 2023: Rakovina Therapeutics Inc. Announces Q1 2023 Financial Results and Provides Corporate Update

May 29, 2023: Rakovina Therapeutics Inc. Announces Closing of $1.5 Million Convertible Debenture Financing

May 1, 2023: Rakovina Therapeutics Inc. Announces 2022 Financial Results and Convertible Debenture Financing

April 20, 2023: Rakovina Therapeutics Announces Presentation of New kt-3000 Series Data at AACR Annual Meeting

April 17, 2023: Rakovina Therapeutics to Present at the Emerging Growth Conference on April 19, 2023

Mar 30, 2023: Rakovina Therapeutics Inc. Announces Enhanced Liquidity and Investor Awareness Programs 

Mar 22, 2023: Rakovina Therapeutics Receives Funding to Accelerate Development of Novel Cancer Therapies

Jan 26, 2023: Rakovina Therapeutics Announces Presentation at the 6th Annual DDRinhibitors Summit

Nov 23, 2022: Rakovina Therapeutics to Present at the Emerging Growth Conference on November 30, 2022

Nov 17, 2022: Rakovina Therapeutics Inc. Announces Q3 2022 Financial Results and Provides Corporate Update

Nov 14, 2022: Rakovina Therapeutics Announces Publication Highlighting Activity of Novel Bi-functional PARP-HDAC Inhibitor in Preclinical Models of Ewing Sarcoma

Oct 31, 2022: Rakovina Therapeutics Announces Preclinical Data Presentation at the 34th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium

Sept 28, 2022: Rakovina Therapeutics Announces Upcoming Scientific Conference Presentations

August 11, 2022: Rakovina Therapeutics Inc. Announces Q2 2022 Financial Results and Provides Corporate Update

June 23, 2022: Rakovina Therapeutics Announces Results from Annual General Meeting

May 26, 2022: Rakovina Therapeutics Inc. Announces Q1 2022 Financial Results and Provides Corporate Update 

May 11, 2022: Rakovina Therapeutics Presents Preclinical Data on its Novel kt-3000 Series at the 2022 AACR Special Conference on Sarcomas

April 27, 2022: Rakovina Therapeutics Inc. Announces 2021 Financial Results and Provides Corporate Update

April 12, 2022: Rakovina Therapeutics Presents Preclinical Data Supporting Potential Broad Anticancer Activity of kt-4000 Series at the American Association of Cancer Research (AACR)

March 30, 2022: Rakovina Therapeutics to Present Abstract at the 2022 AACR Special Conference – Sarcomas

March 09, 2022: Rakovina Therapeutics to Present Abstract at the 2022 Annual Meeting of the American Association of Cancer Research (AACR)

February 21, 2022: Rakovina Therapeutics preventing cancer cells from making DNA repairs they need to survive

January 25, 2022: Rakovina Therapeutics President to Join Expert Panel at the Fifth Annual DDR, ATR & PARP Inhibitors Summit

January 06, 2022: Rakovina Therapeutics Inc. to Present at Biotech Showcase 2022

December 21, 2021: Rakovina Therapeutics Announces Non-dilutive Financial Contributions to Support Lead Optimization of Novel Anti-cancer Agents

November 23, 2021: Rakovina Therapeutics Inc. Announces Third Quarter 2021 Financial Results and Provides Corporate Update

November 16, 2021: Rakovina Therapeutics Partners with St. Baldrick’s Foundation to Research and Develop New Treatments for Childhood Bone Cancer

November 11, 2021: Rakovina Therapeutics Presents at the 6th biennial Canadian Cancer Research Conference

October 21, 2021: Rakovina Therapeutics to Present at the 6th biennial Canadian Cancer Research Conference

October 12, 2021: Rakovina Therapeutics Presents at the 2021 AACRNCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

October 7, 2021: Rakovina Therapeutics Inc. Receives Notice of Allowance for New U.S. Patent Covering kt-2000 series PARP Inhibitors

September 16, 2021: Rakovina Therapeutics Presents Preclinical Data on novel kt-3000 Series Drug Candidates at JCA-AACR Precision Medicine International Conference 

September 9, 2021: Rakovina Therapeutics to Present at the JCA-AACR Precision Medicine International Conference 

August 26, 2021: Rakovina Therapeutics Inc. Announces Second Quarter 2021 Financial Results and Provides Corporate Update

August 17, 2021: Rakovina Therapeutics to Present at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

June 29, 2021: Rakovina Therapeutics Announces Results from Annual General Meeting

June 17, 2021: Rakovina Therapeutics to Present at at The Emerging Growth Conference on June 23, 2021

May 27, 2021: Rakovina Therapeutics Inc. Announces First Quarter 2021 Financial Results and Provides Corporate Update

April 29, 2021: Rakovina Therapeutics Inc. Announces Inaugural Scientific Advisory Board

April 8, 2021: Rakovina Therapeutics Inc. Receives European and Canadian Patents on kt-2000 series PARP-inhibitors

April 5, 2021: Rakovina Therapeutics Inc. Appoints Biotechnology Industry Veteran Julie M. Cherrington, PhD to Board of Directors

April 1, 2021: Rakovina Therapeutics Inc. Commences Trading on TSX Venture Exchange Under Ticker Symbol “RKV”

March 25, 2021: Rakovina Therapeutics Inc. (Formerly Vincero Capital Corp.) Announces Closing of Qualifying Transaction

March 19, 2021: Vincero Capital Corp. Announces Filing of Filing Statement in Connection with Qualifying Transaction

March 12, 2021:  Vincero Capital Corp. Receives Conditional Approval of TSX Venture Exchange for Qualifying Transaction with NewGen Therapeutics, Inc. and Announces Over-Subscribed Financing

November 10, 2020:  Vincero Capital Provides Update on Qualifying Transaction

Presentations

Virtual Investor Conferences

November 2021: CCRC 2021 poster presentation

October 2021: AACR-NCI-EORTC presentation

Events

American Association of Cancer Research Annual Meeting

 

AACR Special Conference on Sarcomas

 

In the News

Red Thread Ventures’ portfolio company Rakovina Therapeutics’

Edison Oncology, Rakovina Therapeutics Partner on PARP Inhibitor Program

Cells: DNA Damage: From Threat to Treatment

The Wall Street Journal: Scientists Work on DNA Repair Earns Nobel Prize in Chemistry